reason report
copaxon headwind off-set save stabl gx austedo/
bottom line believ con estim come
given greater-than-expect impact copaxon eros
believ guidanc continu appropri rang
hit us gener continu show stabil potenti
key product launch expect like gx forteo nuvar
restasi continu perform austedo ajovi
continu benefit cost ration run rate
alreadi achiev howev remain unclear whether teva
drive top-lin growth despit addit potenti competit
entrant copaxon remain
consensu sale get y/i top-lin growth
per manag expect current estim
vs prior although earn growth continu look
achiev reiter market perform rate pt
chang model lower revenu
lower revenu north america
row higher revenu eu also greater
convict manag reduc cost base
overal chang lower ep
ebitda
lower half guidanc rang chang also lower
ebitda slightli continu use ev/ebitda
multipl result chang pt
global copaxon guidanc lower
see achiev top-lin miss
primarili due na copaxon half declin due
inventori half due price expect see larg
cumul impact go forward see higher na copaxon
revenu vs may see new competit entrant
assum believ manag
us copaxon guidanc assum addit competit well
see guidanc target achiev also see potenti
eu copaxon revenu come higher current estim
teva move enforc patent country-by-countri basi
ajovi continu track reach guidanc
manag see ajovi hold marketplac
new-to-brand prescript nbrx share pleas share
voic among neurologist key headach center gross-to-net
come higher origin anticip manag see
trend north go forward howev teva continu improv
posit script get reimburs vs
coverag decis market continu fluid manag
compani inform svb leerink llc research
revenu adjust non-gaap ep present
ev/ebitda multipl
ebitda
net debt total capit
gener unless otherwis note
year price history/av daili volume mil teva
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
note coverag caremark op ci
op got access express script ci april although
unitedhealthcar op see payer discuss continu
note access commerci live
point suffici reach goal manag
acknowledg pre-fil syring may slight drag nbrx
share look get autoinjector market later
year overal manag see everi month dose
potenti autoinjector pre-fil syring option benefit
could also oral cgrp come market eu manag
start gradual roll-out germani scandinavia countri
note price could similar potenti higher us
although minim sale expect estim
austedo continu grow tardiv dyskinesia indic
guidanc remain track manag note
tardiv dyskinesia td market remain earli stage
ampl room austedo mp ingrezza given high
unmet need austedo commerci part coverag
manag note gain advantag access vs ingrezza
ultim expect price eros occur market
us gener market continu show stabil look
potenti launch key product opportun manag
continu indic stabil us gener epipen
manag continu look get gener pediatr version
approv time back-to-school season manag continu
put forteo first-to-market ftm opportun longer term
manag expect limit competit market given
product complex nuvar continu guid
decis restasi come early-to-mid summer
addit takeaway manag see us qvar
revenu good quarterli run rate
anticip choppi seen take place year
row revenu impact season continu headwind
japan sequenti manag see revenu
improv cours year believ japan could stabil
manag see sale market increas
cost base could end lower
guid would like come line
gross margin consid floor manag
believ maintain year grow outer year longer-
term oper margin goal remain
attribut neutral outlook due five main factor brand copaxon start
see increment eros new gener entrant austedo build strong perform
proair eros gener albuterol inhal like signific impact year
ajovi trx continu ramp sale contribut remain nebul cost
may trend much manag initi guidanc still see risk
consensu number believ matter time meaning gener
competit hit copaxon proair could still downsid addit gener
still struggl see growth us gener believ manag done good job
stabil busi build block place busi grow start
rate teva market perform price target
price target base ebitda ev/ebitda multipl
line gx peer group teva lupin hik rdi ev/ebitda
continu delay new gener opportun slower-than-anticip ramp ajovi could
result teva trade lower price target addit delay gener competit
copaxon proair along faster growth austedo could result teva trade
note number
figur chang model
svb leerink estim note number except ep
figur chang model continu
svb leerink estim note number except ep
total cost summat cog sg
note number except ep
teva varianc analysissvb leerinkami fadiaconfer call analystdi changevalu changevarianceconsensusactual-consproductnorth north america north america europ europ growth market growth market assoc dilut non-gaap adjustmentstot one-tim net teva ltd
brand
type event
event trial detail
date known
up/down
expect
safeti data on-going
result phase
svb leerink llc equiti research compani file
number except per share data
share assoc co
net debt ebitda ratio
number except per share data
number except per share data
disclos ftf notabl pipelin
restasi patent invalid await appeal assum launch pend approv
letairi approv end march
renvela assum approv pend approv
noxafil drt assum compound patent expir jul hold pend approv
nuvar appeal state patent valid pend approv
zubsolv sept patent upheld court pend approv
latuda lost jan patent tent approv
rozerem undisclos settlement assum jul compound expiri approv
zyclara settlement jul pend approv
vigamox assum month patent expiri approv
number except per share data
abraxan ode exclus pend approv
absorica settlement dec pend approv
silenor settlement jan exclus approv
tarceva undisclos settlement assum may expiri polymorph patent pend approv
diclegi assum month patent expiri approv
atripla/truvada undisclos settlemnet assum last patent emtricitabin expir gate approv
rayo settlement approv
xopenex hfa assum month patent expiri pend approv
onglyza franchis patent upheld court pend approv
disclos ftf notabl pipelin sub-tot
number except per share data
number except per share data
number except per share data
number except per share data
asset held sale
sale reserv allow
liabil held sale
tax long-term liabil
senior note loan
number except per share data
adjust reconcil ni net cash oper
impair long-liv asset
net gain loss sale long-liv assets/invest
translat adjust due venezuela devalu
research develop process
impair equiti invest net
decreas increas work capit
sale purchas busi net cash acquir
proce sale long-liv asset invest
purchas properti plant equip capital-expenditure
purchas invest asset
net invest
dividend paid ordinari share
proce issuance/ purchas ordinari share net
proce issuanc prefer share net
dividend paid prefer share
dividend paid non-control interest
proce exercis option employe
purchas treasuri shares/ ordinari share
net financ
translat adjust cash cash equival
net chang equival
